Skip to content
Nisoldipine
Sular (nisoldipine) is a small molecule pharmaceutical. Nisoldipine was first approved as Sular on 1995-02-02. It is used to treat hypertension and variant angina pectoris in the USA. It is known to target voltage-dependent L-type calcium channel subunit alpha-1C and voltage-dependent L-type calcium channel subunit alpha-1D.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
cardiovascular diseasesD002318
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Sular (generic drugs available since 2008-07-25)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Nisoldipine
Tradename
Company
Number
Date
Products
SULARCovis PharmaN-020356 RX2008-01-02
3 products, RLD, RS
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
sularNew Drug Application2019-12-13
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
hypertensionEFO_0000537D006973I10
variant angina pectoris—D000788I20.1
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
— C08: Calcium channel blockers
— C08C: Selective calcium channel blockers with mainly vascular effects
— C08CA: Dihydropyridine derivative selective calcium channel blockers with mainly vascular effects
— C08CA07: Nisoldipine
HCPCS
No data
Clinical
Clinical Trials
164 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Idiopathic pulmonary fibrosisD054990J84.1123336924
Interstitial lung diseasesD017563EFO_0004244J84.89——71917
Pulmonary fibrosisD011658J84.10—33129
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Non-small-cell lung carcinomaD0022891463——21
Ovarian neoplasmsD010051EFO_0003893C56341——8
Colorectal neoplasmsD015179—41——5
Peritoneal neoplasmsD010534111——3
Systemic sclerodermaD012595EFO_0000717M341—1——2
MesotheliomaD008654C45—11——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—121———13
Renal cell carcinomaD00229223———4
Myeloid leukemia acuteD015470C92.022———3
GlioblastomaD005909EFO_000051513———3
Prostatic neoplasmsD011471C6112———3
Breast neoplasmsD001943EFO_0003869C5012———3
Liver neoplasmsD008113EFO_1001513C22.012———3
Hereditary hemorrhagic telangiectasiaD013683I78.0—2———2
Uterine cervical neoplasmsD00258311———2
Fallopian tube neoplasmsD005185—2———2
Show 31 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369C808————8
Female genital neoplasmsD0058331————1
Hepatic insufficiencyD0485501————1
Multiple myelomaD009101C90.01————1
Drug interactionsD0043471————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
MyositisD009220EFO_0000783G72.49————11
Lung diseasesD008171EFO_0003818J98.4————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameNISOLDIPINE
INNnisoldipine
Description
Methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate is a dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a methoxycarbonyl group at position 3, an o-nitrophenyl group at position 4, and an isobutoxycarbonyl group at position 5. The racemate, a calcium channel blocker, is used in the treatment of hypertension and angina pectoris. It is a C-nitro compound, a diester, a dihydropyridine, a methyl ester and a member of dicarboxylic acids and O-substituted derivatives.
Classification
Small molecule
Drug classphenylpyridine vasodilators; tricyclic compounds
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1c1ccccc1[N+](=O)[O-]
Identifiers
PDB—
CAS-ID63675-72-9
RxCUI7435
ChEMBL IDCHEMBL1726
ChEBI ID76917
PubChem CID4499
DrugBankDB00401
UNII ID4I8HAB65SZ (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
CACNA1C
CACNA1C
CACNA1D
CACNA1D
Organism
Homo sapiens
Gene name
CACNA1C
Gene synonyms
CACH2, CACN2, CACNL1A1, CCHL1A1
NCBI Gene ID
775
Protein name
voltage-dependent L-type calcium channel subunit alpha-1C
Protein synonyms
CACNA1C intronic transcript 2, CACNA1C intronic transcript 2 (non-protein coding), calcium channel, cardic dihydropyridine-sensitive, alpha-1 subunit, Calcium channel, L type, alpha-1 polypeptide, isoform 1, cardiac muscle, calcium channel, voltage-dependent, L type, alpha 1C subunit, DHPR, alpha-1 subunit, voltage-dependent L-type Ca2+ channel alpha 1 subunit, Voltage-gated calcium channel subunit alpha Cav1.2
Uniprot ID
Q13936
Mouse ortholog
Cacna1c (12288)
voltage-dependent L-type calcium channel subunit alpha-1C (Q99242)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 1,535 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
13,778 adverse events reported
View more details